Clinical trials: Psychosis;Schizophrenic
Schizophrenia, Cognition
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking.
- Conditions
- Schizophrenia, Cognition, Cigarette Smoking
- Trial name
- TDCSSCHIZ (NCT02128919)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Metabolic Evaluation, Cardiac Complications
Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects
The therapeutic use of ALA in schizophrenia has recently been investigated in human populations. A case series explored the effiacy of ALA as a novel agent to treat antipsychotic-induced obesity, at a dose of 1200 mg/d (range…
- Trial name
- NCT06787781
- Testing
- Alpha Lipoic Acid
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Messina
Schizophrenia; Psychosis
The IM-ZBULLE Study : " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate
Intramuscular injection (IMI) is the process of administering a drug treatment into muscle tissue. The transmission of skills in this care practice is essentially based on the experience of peers.
- Trial name
- IM-ZBULLE (NCT05995457)
- Testing
- Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques, Intramuscular injection of Haloperidol decanoate using standard techniques
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
- Trial name
- NCT00487942
- Testing
- armodafinil
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cephalon
Schizophrenia
A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone
The purpose of this research study is to measure how many of the dopamine receptors lurasidone occupies throughout the brain of patients with schizophrenia or schizoaffective disorder and over what time period the occupancy…
- Trial name
- NCT01979679
- Testing
- Lurasidone 80 mg, Lurasidone 120 mg, Lurasidone 160 mg
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, Irvine
Schizophrenia, Drug Abuse/Dependency
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
Background: Individuals with schizophrenia have a significantly higher tendency to develop substance abuse or dependence than the general population.
- Trial name
- NCT01037075
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients.
- Trial name
- NCT00364429
- Testing
- [123]I-CNS 1261, Lorazepam, Risperidone
- Where
- Spain
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
The purpose of this study is to explore the pharmacokinetic profile and safety after biweekly (every 2-week) intramuscular (IM) injections (6 injections) of risperidone long acting injectable 25, 37.5, or 50 mg/dose in…
- Trial name
- NCT00653406
- Testing
- Risperidone long acting injectable
- Volunteers
- 29 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
- Trial name
- NCT00396214
- Testing
- Bifeprunox, Quetiapine
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 83 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia
Four Dimensions in Schizophrenia
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6.
- Trial name
- 4D (NCT00782899)
- Where
- 65 sites in Spain
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Schizophrenia
In-Patient Study In Schizophrenic Patients
This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days.
- Trial name
- NCT00197093
- Testing
- SB773812
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine.
- Trial name
- NCT00056498
- Testing
- Risperdal
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia and Related Disorders
Clay Therapy in Schizophrenia Patients
In recent years, art therapies have been discussed for their positive effects on mental disorders. One such therapy, clay therapy, is being studied to examine its effect on the functional recovery and individual and social…
- Trial name
- NCT07378150
- Testing
- Clay therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 17 people
- Sponsor
- Kutahya Health Sciences University
Schizophrenia, Negative Type; Schizophrenic
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia.
- Conditions
- Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
- Trial name
- NCT03648268
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia is a brain disease. The condition may be associated with acute psychotic episodes and long-term disability despite remission from the acute symptoms.
- Trial name
- NCT00150176
- Testing
- Asenapine - Open Label, Asenapine - Double Blind
- Volunteers
- 831 people
- Sponsor
- Organon and Co
Schizophrenic Disorders
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine…
- Trial name
- NCT00088491
- Testing
- Intramuscular Olanzapine Depot, Oral Olanzapine
- Where
- 4 sites in Finland, Turkey (Türkiye)
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous…
- Trial name
- NCT00313391
- Testing
- Risperdal Consta
- Where
- United States
- Sponsor
- Emory University
Schizophrenic Disorder, Cognitive Impairment
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
The purpose of this grant is to evaluate the efficacy of sodium butyrate as a novel treatment for cognitive deficits in schizophrenia (SZ).
- Trial name
- NCT03010865
- Testing
- Sodium Butyrate
- Where
- China
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Links Between Perception of Temporal Order Judgment and Causality in Schizophrenia
People with schizophrenia show disturbances in the perception of time. Among these alterations are the perturbations of the temporal order judgment.
- Trial name
- TOCAS (NCT03432000)
- Testing
- Performances of patients and controls on temporal task
- Where
- France
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Schizophrenic Disorders
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
This study evaluates the effect of a cognitive remediation program on neurocognitive, social cognitive and metacognitive functions designed for patients living with a schizophrenia spectrum disorder.
- Trial name
- NARCIS (NCT04608032)
- Testing
- [Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder, Recovery-Oriented Therapy
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France